Newly-released Gastro-retentive Drug Delivery Systems industry analysis report by Future Market Insights reveals that global sales of Gastro-retentive Drug Delivery Systems in 2022 were held at US$ 13.3 Billion. With a CAGR of 10.1% from 2023 to 2033, the market is expected to reach US$ 24.8 Billion by 2033. Floating Drug Delivery System is expected to be the highest revenue generating type, with a CAGR of 5% from 2023 to 2033.
Attribute | Details |
---|---|
Global Gastro-retentive Drug Delivery Systems Market (2023) | US$ 14 Billion |
Global Gastro-retentive Drug Delivery Systems Market (2033) | US$ 24.8 Billion |
Global Gastro-retentive Drug Delivery Systems Market CAGR (2023 to 2033) | 10.1% |
USA Gastro-retentive Drug Delivery Systems Market CAGR (2023 to 2033) | 6% |
Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Gastro-retentive Drug Delivery Systems industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, market value of the Gastro-retentive Drug Delivery Systems industry increased at a CAGR of around 8.6%, wherein, countries such as the USA, China, Japan, United kingdom and South Korea held a significant share in the global market.
Rising disease burden throughout the world and the proven efficacy of GRDDS in addressing several gastric-related disorders such as gastric ulcers, and peptic ulcers, are some of the key reasons driving the market growth. Owing to this, the gastro-retentive Drug Delivery Systems market is projected to grow at a CAGR of 10.1% over the coming 10 years.
Manufacturing systems, formulation approaches, storage systems, and technologies involved in transporting a drug to its gastrointestinal target site make gastro-retentive drug delivery global sales. Medical professionals are making use of the principles of production, rental property, locality of prescription, metabolism, and toxicity to boost the safety and potency of a drug delivery system. By making use of a gastro-retentive delivery system, illnesses can be prevented and treated using nutrients.
Large drug firms' investments to enhance gastro-retentive drug-delivery systems, along with the reduction in required doses due to enhanced bioavailability and an increase in the requirements for medications, have helped accelerate the market growth. The well-established efficacy of gastro-retentive drug delivery systems in treating a variety of stomach disorders such as peptic ulcer and gastric ulcer, as well as a growth in the incidence of H. Pylori infection, which can cause gastritis and gastric cancer, impart a significant impact on the market.
Gastro-retentive drug distribution technology has proven to be a useful way of regulating the administration of a wide range of medicinal substances while enhancing bioavailability. Advancements in controlled oral medication administration systems have been made in recent years because of technological advancements that overcome physical roadblocks such as unpredictable stomach emptying periods and short gastric residency times. By extending their dwell time in the upper GI tract, once-GRDDS can enhance oral bioavailability and therapeutic excellence.
Technological advancements for rate-controlled oral medication delivery systems are now overcoming physiological issues such as unexpected stomach emptying intervals and short gastric residency times. To address these issues, the gastro-retentive drug delivery system is designed for a longer stomach retention duration, which increases patient preference by extending the time available for medicine absorption.
North America is expected to account for significant revenue in gastro-retentive drug delivery systems market, with a market projection of US$ 10 Billion. Regional expansion is expected to be facilitated by the introduction of improved gastro-retentive medication delivery technology and the implementation of novel treatment techniques in healthcare.
GRDDS are projected to be in high demand as the prevalence of gastrointestinal disorders grows in the United States and Canada, as they lengthen medication retention time in the stomach. Demand for these devices in the region is projected to be driven by the presence of a large patient pool. Rising research and development spending in emerging markets is expected to drive regional market expansion.
Gastro-retentive Drug Delivery Systems Market in the US is expected to grow at a CAGR of 6% during the forecast period. The high prevalence of gastric cancer in the United States, as well as increasing research and development investment have contributed to the large market in the country.
The market in the United kingdom is expected to reach a valuation of US$ 1 Billion by 2033. Growing with a CAGR of 6.1% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of around US$ 400 Million.
In Japan, the market is expected to grow at a CAGR of 7.2% from 2023 to 2033, reaching around US$ 1 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 500 Million during the forecast period.
The market in South Korea is expected to reach a valuation of around US$ 700 Million by 2033, growing at a CAGR of 7.3% from 2023 to 2033. The market in the country is expected to witness an absolute dollar opportunity of around US$ 400 Million.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Floating Drug Delivery systems are expected to account for significant market revenue and are expected to grow at a CAGR of 5% during the forecast period. Using floating medication delivery devices is one of the most important ways for improving stomach retention and drug bioavailability. Due to this, the system has a lower bulk density than gastric fluids, it may stay buoyant in the stomach for extended periods of time without interfering with the process of gastric emptying.
This mechanism gradually and at a predetermined rate delivers the drug. When medicine is administered, the stomach's residual system is emptied. This improves segmental development by lengthening stomach retention and better control over changes in plasma medicine concentration.
Manufacturers will benefit from proprietary benefits such as industry research financing and product development agreements, which will help them contribute to the development of effective cancer diagnosis technologies. Obtaining patents and government clearances for new technology will also continue to be a key growth strategy.
The key players in the market include Ranbaxy, F. Hoffmann La Roche, Pharmacia, GlaxoSmithKline, Lupin, Pfizer, Depomed, Galanix, Sun Pharma, and Alcon, Inc.
Few of the recent developments of key Gastro-retentive Drug Delivery Systems providers are as follows:
Similarly, recent developments related to companies offering Gastro-retentive Drug Delivery Systems have been tracked by the team at Future Market Insights, which are available in the full report.
The market is expected to attain a value of US$ 14 billion in 2023.
Large drug firms' investments and technological advancements are driving the market growth.
North America is expected to offer significant opportunity for gastro-retentive drug delivery systems.
Floating drug delivery systems are highly preferred in the market.
The South Korea market is expected to expand at a CAGR of 7.3%.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type , 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type , 2023 to 2033
5.3.1. High Density System
5.3.2. Expandable Drug Delivery System
5.3.3. Bioadhesive Drug Delivery System
5.3.4. Floating Drug Delivery System
5.3.5. Other Types
5.4. Y-o-Y Growth Trend Analysis By Type , 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type , 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dosage Form
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Dosage Form, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033
6.3.1. Tablets
6.3.2. Liquid
6.3.3. Microspheres
6.3.4. Capsule
6.3.5. Other Dosage Forms
6.4. Y-o-Y Growth Trend Analysis By Dosage Form, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Dosage Form, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Dosage Form
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Dosage Form
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Dosage Form
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Dosage Form
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. United kingdom
11.2.1.5. Russia
11.2.1.6. BENELUX
11.2.1.7. Rest of Europe
11.2.2. By Type
11.2.3. By Dosage Form
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Dosage Form
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Rest of Asia Pacific
12.2.2. By Type
12.2.3. By Dosage Form
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Dosage Form
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Turkey
13.2.1.4. Rest of Middle East and Africa
13.2.2. By Type
13.2.3. By Dosage Form
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Dosage Form
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Type
14.1.2.2. By Dosage Form
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Type
14.2.2.2. By Dosage Form
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Type
14.3.2.2. By Dosage Form
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Type
14.4.2.2. By Dosage Form
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Type
14.5.2.2. By Dosage Form
14.5.2.3. By Distribution Channel
14.6. Italy
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Type
14.6.2.2. By Dosage Form
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Type
14.7.2.2. By Dosage Form
14.7.2.3. By Distribution Channel
14.8. United kingdom
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Type
14.8.2.2. By Dosage Form
14.8.2.3. By Distribution Channel
14.9. Russia
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Type
14.9.2.2. By Dosage Form
14.9.2.3. By Distribution Channel
14.10. BENELUX
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Type
14.10.2.2. By Dosage Form
14.10.2.3. By Distribution Channel
14.11. China
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Type
14.11.2.2. By Dosage Form
14.11.2.3. By Distribution Channel
14.12. Japan
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Type
14.12.2.2. By Dosage Form
14.12.2.3. By Distribution Channel
14.13. South Korea
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Type
14.13.2.2. By Dosage Form
14.13.2.3. By Distribution Channel
14.14. GCC Countries
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Type
14.14.2.2. By Dosage Form
14.14.2.3. By Distribution Channel
14.15. South Africa
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Type
14.15.2.2. By Dosage Form
14.15.2.3. By Distribution Channel
14.16. Turkey
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Type
14.16.2.2. By Dosage Form
14.16.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Type
15.3.3. By Dosage Form
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. F. Hoffmann La Roche
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Ranbaxy
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. GlaxoSmithKline
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Pharmacia
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Depomed
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Alcon, Inc.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Lupin
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Galanix
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Sun Pharma
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports